Dr. Omar Alshaer presents a real patient case*:
A case study of HR+, HER2- ABC with metastases beyond the bone, a concerning clinical characteristic1-4
Disease characteristics that typically confer a less favorable prognosis. Visceral and bone metastases were a concerning clinical characteristic in MONARCH 2. Pre-planned subgroup analyses of OS and PFS were performed in the pre- or perimenopausal population.
For more information, see page 5.
Dr. Omar Alshaer, MD, is Head Section of medical oncology on Security Forces Hospital in Riyadh.
*Patient name is kept anonymous to maintain confidentiality
This case study presents a real patient and disease characteristics. The efficacy of abemaciclib in combination with fulvestrant (FUL) is sourced from MONARCH 2, the Verzenio + FUL trial.
This clinical case presentation has been sponsored by Eli Lilly and Company.
Verzenio is indicated for the treatment of hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2−) advanced or metastatic breast cancer (MBC)1:
• In combination with fulvestrant for women with disease progression following endocrine therapy
• In combination with an aromatase inhibitor (AI) for postmenopausal women as initial endocrine-based therapy
• As a single agent for adult patients with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting
PP-AL-SA-0390Please see Select Important Safety Information throughout, and full Prescribing Information for Verzenio.